
GORE® ENFORM Biomaterials with GORE 3D Bioabsorbable Technology

SHAPE THE FUTURE OF TISSUE REGENERATION




Rapid tissue incorporation to promote Type 1 collagen generation for predictable outcomes.*,1



More incorporation

See the difference 7 days after implantation vs. leading acellular dermal matrices (ADMs)¹

Total Cellular In-Growth



- MTF BIOLOGICS® FLEXHD STRUCTURAL® Acellular Hydrated Dermis
- ALLERGAN® STRATTICE® Reconstructive Tissue Matrix
- COVIDIEN® PERMACOL® Surgical Implant

Lower cost than ADMs*

GORE® ENFORM Biomaterials eliminate the tissue processing costs associated with ADMs in complex applications, making the average cost almost 50% lower than equivalent-sized ADMs.*

\$5K Savings compared to the cost of ADMs

*Data on file, W. L. Gore & Associates, Inc; Flagstaff, AZ.

ALLERGAN is a trademark of Allergan, Inc. COVIDIEN and PERMACOL are trademarks of Covidien AG. ${\it STRATTICE} \ is \ a \ trademark \ of \ Lifecell \ Corporation, \ an \ Allergan \ affiliate.$ MTF BIOLOGICS and FLEXHD STRUCTURAL are trademarks of Musculoskeletal Transplant Foundation, Inc.

Count on predictable, reliable performance minimizing long-term complications

GORE 3D Bioabsorbable Technology delivers:

Zero complete removals reported due to infection*




Zero reports of erosion in clinical literature over 10 years²



LOW inflammatory response³ and minimized seroma²

Our technology: 0-7.7% vs. ADMs: 2.4-32.3%^{2,4}

LOW inflammatory response



Mesh type/Controls

GORE 3D Bioabsorbable Technology demonstrated a LOW inflammatory response vs. the leading ADMs³

- *A literature search was performed by an Information Specialist in January 2024 using the EMBASE® Database and DIMENSIONS Database. Key words/phrases are on file.
- † Data on file, W. L. Gore & Associates, Inc; Flagstaff, AZ.

ALLERGAN and ALLODERM are trademarks of Allergan, Inc.

BD and ALLOMAX are trademarks of C.R. Bard, Inc. EMBASE is a trademark of Elsevier B.V. MTF BIOLOGICS and FLEXHD STRUCTURAL are trademarks of Musculoskeletal Transplant Foundation, Inc.



Minimize risk

ENFORM Biomaterials promote tissue incorporation and rapid vascularization which helps with the ability to treat the device if a postoperative infection occurs $^{\rm t,l,2}$

Easy to use with soft conformability that fits your patients and your technique



No need to be tissue-tracked



No human or animal sources



No refrigeration needed for a 3-year shelf life



No soaking necessary before implantation

Provides optimal pore size⁵

Rapidly builds healthy native tissue with lower inflammation in as little as 7 days

The textured, porous GORE 3D Bioabsorbable Technology built into ENFORM Biomaterials:

- Allows fluids and nutrients to pass through, facilitating rapid cell infiltration and encouraging fast revascularization*,5
- Absorbs into the body as the device is integrated with a low inflammatory response, leaving uniform, dense collagen in its place*,1,3
- Is backed by more than 20 years of research and clinical use²



^{*} Data on file, W. L. Gore & Associates, Inc; Flagstaff, AZ.

GORE® ENFORM Biomaterials

Welcome to the future of tissue generation

Rapid tissue incorporation to promote Type 1 collagen generation for predictable outcomes*,1:

Predictable, reliable performance minimizing long-term complications²

Easy to use with soft conformability that easily fits your patients and your technique

Optimal pore size to rapidly build healthy native tissue with lower inflammation in as little as 7 days⁵

Lower cost than ADMs*


Uniquely pliable performance and can be cut to size.



Scan to see available



To learn more reach out to your Gore Plastic Specialist.



References

1. Zemlyak A, Colavita P, Tsirline V, et al. Absorbable glycolic acid/trimethylene carbonate synthetic mesh demonstrates superior in-growth and collagen deposition. Presented at the 4th Annual European Plastic Surgery Research Council (EPSRC) Meeting; August 23-26, 2012; Hamburg, Germany. *Plastic & Reconstructive Surgery* 2012;130(Supplement 25):493. Abstract LOP59

2. W. L. Gore & Associates, Inc. *Clinical Evaluation Report for GORE® BIO-A® Tissue Reinforcement*. Flagstaff, AZ: W. L. Gore & Associates, Inc; 2024. [Clinical Evaluation Report - CER]. MD114935. Rev 14.

3. Orenstein SB, Qiao Y, Kaur M, Klueh U, Kreutzer DL, Novitsky YW. Human monocyte activation by biologic and biodegradable meshes in vitro. *Surgical Endoscopy* 2010;24(4):805-811.

4. Samson, DJ, Gachabayov M, Latifi, R. Biologic Mesh in Surgery: A Comprehensive Review and Meta-Analysis of selected outcomes in 51 studies and 6079 patients. *World Journal of Surgery* 2021;45(12):3524-3540.

5. Sharkawy AA, Klitzman B, Truskey GA, Reichert WM. Engineering the tissue which encapsulates subcutaneous implants. II. Plasma-tissue exchange properties. *Journal of Biomedical Materials Research* 1998;40(4):586-97.

Consult Instructions for Use eifu.goremedical.com

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. $R_{X \text{ Only}}$

Products listed may not be available in all markets.

ALLERGAN and ALLODERM are trademarks of Allergan, Inc. BD and ALLOMAX are trademarks of C.R. Bard, Inc. COVIDIEN and PERMACOL are trademarks of Covidien AG. EMBASE is a trademark of Elsevier B.V.

STRATTICE is a trademark of Lifecell Corporation, an Allergan affiliate.

MTF BIOLOGICS and FLEXHD STRUCTURAL are trademarks of Musculoskeletal Transplant Foundation, Inc.

GORE, Together, improving life, BIO-A, ENFORM and designs are trademarks of W. L. Gore & Associates.

© 2024 W. L. Gore & Associates, Inc. 241384602-EN APRIL 2024

